Evidence map›Paper›PMID 37012466›Full record

ArticleJournal of neurology2023

Translocator protein (TSPO)-PET as diagnostic and monitoring tool in COVID-19 related MRI-negative brainstem encephalitis: a case report.

Johannes Wischmann, Laura M Bartos, Matthias Brendel, Nathalie L Albert, Robert Forbrig, Andreas Straube, Ilias Masouris

Open access · hybridAbstract readCase ReportsLetter
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Persistent dysfunctions of brain metabolic connectivity in long-covid with cognitive symptoms.European journal of nuclear medicine and molecular imaging · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Johannes WischmannDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany. Johannes.wischmann@med.uni-muenchen.de.ORCID http://orcid.org/0000-0003-0653-943X
Laura M BartosDepartment of Nuclear Medicine, University, Ludwig-Maximilians-University (LMU), Munich, Germany.
Matthias BrendelDepartment of Nuclear Medicine, University, Ludwig-Maximilians-University (LMU), Munich, Germany.
Nathalie L AlbertDepartment of Nuclear Medicine, University, Ludwig-Maximilians-University (LMU), Munich, Germany.
Robert ForbrigInstitute of Neuroradiology, University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany.
Andreas StraubeDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany.
Ilias MasourisDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany.
Ludwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEncephalitis and myelitis have been linked to both COVID-19 vaccination and infection, causing symptoms such as reduced consciousness, mental state alterations and seizures. Remarkably, most cases do not show significant structural alterations on MRI scans, which poses a diagnostic challenge.

methodsWe present the diagnostic workup and clinical course of a patient who developed a progressive brainstem syndrome two weeks after COVID-19 vaccination and subsequent infection. We used translocator protein (TSPO)-PET scans for the first time to investigate COVID-related neuroinflammation.

resultsThe patient developed oculomotor disorder, dysarthria, paresthesia in all distal limbs and spastic-atactic gait. CSF analysis revealed mild lymphocytic pleocytosis with normal protein levels. Brain and spinal cord MRI scans were negative, but TSPO/PET scans showed increased microglia activity in the brainstem, which correlated with the clinical course. Steroid treatment led to clinical improvement, but relapse occurred during prednisone taper after four weeks. Plasmapheresis had no significant effect; however, complete remission was achieved with cyclophosphamide and methotrexate, with normal TSPO signal ten months after onset.

conclusionsTSPO-PET can be a valuable tool in the diagnostic and therapeutic monitoring of COVID-19-related encephalitis, particularly in cases where MRI scans are negative. Aggressive immunosuppressive therapy can lead to sustained remission.

Indexed as

COVID-19EncephalitisBrain StemCOVID-19 TestingCOVID-19 VaccinesDisease ProgressionHumansMagnetic Resonance ImagingPositron-Emission TomographyReceptors, GABACOVID-19 VaccinesReceptors, GABATSPO protein, humanAutoimmune encephalitisCase reportCOVID-19TSPO-PET

Identifiers

PMID37012466
PMCPMC10069725
OpenAlexW4362523782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.